Bonita David P
SEC-identified person · CIK 1572451 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Imagenebio, Inc. IMA | Director | filed 2021 - 2026 |
| Prelude Therapeutics Inc PRLD | Director | filed 2020 - 2026 |
| Third Harmonic Bio, Inc. THRD | Director | filed 2022 - 2025 |
| Repare Therapeutics Inc. RPTX | Director | filed 2020 - 2024 |
| Acutus Medical, Inc. AFIB | Director | filed 2020 - 2023 |
| Tricida, Inc. TCDA | Director | filed 2018 - 2022 |
| Imara Inc. IMRA | Director | filed 2020 - 2022 |
| SI-Bone, Inc. SIBN | Director | filed 2018 - 2018 |
| Viewray, Inc. VRAY | Director | filed 2016 - 2018 |
| Loxo Oncology, Inc. LOXO | Director | filed 2014 - 2017 |
| Ambit Biosciences Corp AMBI | Director | filed 2013 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.